Niederer Kraft Frey is acting as counsel to Idorsia
Niederer Kraft Frey is acting as counsel to Idorsia in the rights offering that Idorsia launched on October 8th. The targeted gross proceeds from the offering of CHF 575 million will be used to support the regulatory filing and, if approved, commercial launch of daridorexant, Idorsia’s dual orexin receptor antagonist, and to fund the clinical development of its other late-stage compounds as well as early-stage pipeline assets.